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In this cross-sectional population-based study we determine human papillomavirus (HPV) prevalence in South Wales to provide
comprehensive baseline data for future assessment of the impact of prophylactic HPV vaccination and to help inform future screening
strategies. Liquid-based cytology samples from women attending routine cervical screening were collected (n¼10000: mean age 38
years, 93% cytology negative, and 64.8% from the 50% least deprived LSOA according to social deprivation score (SDS)). High-Risk
(HR) and Low-Risk HPV screening was performed using HPV PCR-EIA with genotyping of HR positives and data correlated with age,
SDS and cytology. Overall HPV prevalence was 13.5% (9.3% age standardised) and the most frequent HR types were HPV 16, 31, 18
and 58. In HR HPV-positive cases 42.4% had a single HR type and they were predominant in women with severe cytological
abnormalities. Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV
status. HPV prevalence increased significantly with degree of dyskarosis from 7% in cytology negative samples to 80% in samples with
severe cytological abnormalities (P-value o0.0001). Overall, 46% of HR HPV cases were positive for the two HR types targeted by
the prophylactic vaccines (HPV 16 and HPV 18). The data presented represents the largest type-specific investigation of HPV
prevalence in an unselected UK population.
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Human papillomavirus (HPV) infection is the essential underlying
cause of cervical cancer, found in 99.7% of invasive cervical
carcinomas (Walboomers et al, 1999; Mun ˜oz, 2000; Bo ¨hmer et al,
2003). HPV is a common cause of infection, but most of these are
transient and do not result in cancer (Koutsky, 1997). Worldwide
type-specific HPV prevalence in women with normal cytology is
estimated to be 10.4%, highest in Africa (22.1%) and lowest in Asia
(8.0%) (reviewed in de Sanjose ´ et al, 2007). Prevalence of HPV,
type-specific distribution and cervical cancers vary between
different regions and the five most common high-risk (HR) types
are HPV 16, 18, 31, 58 and 52 with HR types 16 and 18 accounting
for more than 70% of cervical cancer cases worldwide (Bosch et al,
1995; Clifford et al, 2005a,b; Smith et al, 2007).
Multiple HR types occur in up to 43% of HR HPV-positive
women and to date no association has been found between
multiple HR types and progression of cervical neoplasia (Cuschieri
et al, 2004). In contrast, clonal expansion of a single integrated HR
type and cervical neoplasia development has been reported
(Vinokurova et al, 2005). Social deprivation has been associated
with cervical cancer incidence, but other co-factors such as age,
smoking, education and reduced participation in screening also
require consideration (de Sanjose ´ et al, 1997; Krieger et al, 1999;
Parikh et al, 2003).
There are two licensed prophylactic vaccines available,
Cervarixt (GlaxoSmithKline, Middlesex, UK) and Gardasil (Merck,
Hertfordshire, UK), both active against HR HPV types 16 and
18 (Paavonen et al, 2007; Joura et al, 2007). Prophylactic HPV
vaccination represents a major public health breakthrough and has
the potential to prevent 70–75% of cervical cancers in women
vaccinated before contact with the virus, that is, before sexual
debut (Harper et al, 2004; Villa et al, 2005). In October 2007,
recommendations were announced that all 12–13 year old girls
should be offered the vaccine and Cervarixt will be implemented
within the UK from September 2008 (DoH News, 2008 and WAG
News, 2007). Current cervical screening relies on cervical cytology
to identify women at risk of having ‘precancerous’ cervical
intraepithelial neoplasia and this process is estimated to save
around 4500 lives per year in the UK (Peto et al, 2004). Following
implementation of HPV vaccination, the positive predictive value
of cervical cytology will fall alongside the reduction in cytological
abnormalities. Consequently current screening strategies will
become less effective necessitating a change in screening modality.
HPV typing and biomolecular marker assays have the potential to
replace cervical cytology provided they demonstrate clinical utility
and cost-effectiveness and there are a number of ongoing HPV
trials within Europe investigating strategies to address these issues
(Cuzick et al, 2003; Cotton et al, 2006; Coupe ´ et al, 2008; Sargent
et al, 2008).
We aimed to extend preliminary findings (Hibbitts et al, 2006)
and determine the prevalence of HPV among women attending
routine cervical screening and thereby provide baseline data for
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vaccination in South Wales. The findings represent the largest
type-specific investigation of HPV infection in an unselected UK
population (n¼10000; 20–65 years).
MATERIALS AND METHODS
10000 consecutive, anonymous, residual liquid-based cytology
(LBC) screening samples were collected in collaboration with
Cervical Screening Wales over a 5-month time period in 2004
(non-probability convenience sample). This method included all
women attending for routine cervical screening within the
catchment area of Llandough Hospital Cytology Laboratory and
constitutes a representative sample of the screening population in
South Wales. Age, cytology result and Social Deprivation Score
(SDS) were provided for each specimen and inadequate cytology
samples or those from colposcopy clinics were excluded. The study
was approved by South Wales Local Research Ethics Committee.
The LBC samples (Thinprep) were processed by the Cytology
Laboratory according to the British Society of Clinical Cytology
guidelines (NHS Cancer Screening Programmes, 2004). Residual
cell pellets were re-suspended in the alcohol-based liquid and
processed by the HPV Laboratory, Cardiff University. Each LBC
sample was washed and re-suspended in 1ml 10mM Tris pH 7.4.
10ml of recombinant proteinase K was added to a 100ml cell
suspension from each sample, incubated at 561C for 2h, followed
by 1001C for 10min. Samples were refrigerated (41C) for 10min,
centrifuged at 13000r.p.m. for 10min and the supernatant
transferred into a 96-well plate. A PCR for the human b-globin
gene was performed on every DNA sample to determine extraction
efficiency as described earlier (Hibbitts et al, 2006). The GP5/
GP6þ HPV PCR-ELISA method of Jacobs et al (1997) was
performed on all specimens in a 96-well format with minor
modifications. Samples were processed in batches of 96 to increase
throughput and a two-tier method applied: (i) An initial PCR-
ELISA with a cocktail of HR or LR type-specific probes; (ii) A
second PCR-ELISA of all HR-positive samples with genotyping
using 14 individual HR HPV probes: HPV 16; 18; 31; 33; 35; 39; 45;
51; 52; 56; 58; 59; 66 and 68. The initial ‘HR/LR’ and subtyping PCR
was performed in a final volume of 25ml and 100ml respectively.
PCR cycling conditions were 941C 4min, 40 cycles of 941C3 0 s ,
401C9 0s ,7 2 1C 60s followed by 721C 4min. Positive (CaSki) and
negative (water) DNA extraction, PCR and ELISA controls were
included for every 94 samples. Re-analysis of 10% of all samples
processed was undertaken for internal quality assessment pur-
poses. Results were analysed in an automated Excel worksheet and
raw data from each reading at each time point pasted into a
specific position in the datasheet and results are then given as
positive (1) or negative (0). The negative extraction control
included in every 96-well plate serves as the background reading
for which all the other results are compared. A positive result is
equivalent to three times background.
Statistical analysis
Statistical analysis was performed on samples that complied with
the following inclusion criteria: b-globin PCR positive; complete
information available on age, cytology result and SDS; within the
screening age group 20–65 years. The HR HPV prevalence was
age-standardised using the European Standard Population and the
age-standardised rate calculation
P
Si ria/
P
Si (Breslow and Day,
1987; Waterhouse, 2003). Social deprivation was estimated by
linking postcodes to the Welsh Index of Multiple Deprivation
which describes levels of deprivation across Wales with higher
scores indicating greater deprivation (National Assembly for
Wales, 2005). The overall deprivation scores in Wales range from
78.9 to 1.4. Geographical units are termed Lower Layer Super
Output Areas (LSOA) and they are graded according to SDS as
follows: 10% most deprived (41.91–78.9 SDS); 10–20% most
deprived (32.71–41.9 SDS); 20–30% most deprived (26.31–32.70
SDS); 30–50% most deprived (17.91–26.30 SDS); 50% least
deprived LSOA in Wales (1.4–17.9 SDS). The w
2 test was used to
calculate a P-value and 95% confidence intervals (CI) were
calculated where appropriate. All HR HPV-positive cases were
differentiated into those with a single HR type and those with
multiple HR types.
RESULTS
The mean age was 38 years with 29.4% aged between 20–29 years,
25.8% 30–39 years, 23.4% 40–49 years, 15.8% 50–59 years and
5.6% over 60 years old. In this study population, 93% were
cytology negative, 4.7% had borderline changes and 1.4, 0.5 and
0.52% had mild, moderate and severe dyskaryosis respectively. The
distribution of samples according to SDS based on the LSOA
ranking system was 9.5% from the 10% most deprived; 5.6% from
the 10 to 20%; 7.4% from the 20 to 30%; 12.6% from the 30 to 50%;
and 64.8% from the 50% least deprived LSOA in Wales.
Of the 10000 samples processed, 921 did not meet the inclusion
criteria and full statistical analysis was performed on the remaining
9079 samples. Internal quality assessment indicated 93% reprodu-
cibility for b-globin-positive DNA extraction controls and 96%
reproducibility for HR and LR HPV-positive results. Here, 1015 HR
HPV-positive and 209 LR HPV-positive cases were identified. In the
1015 HR HPV-positive cases there were 2007 HR infections and 157
were also positive for LR HPV. Overall HPV prevalence was 13.5%
(n¼1224; 95% CI 11.3–15.9%) with an age standardised HPV
prevalence in the South Wales population of 9.3%.
In HR HPV-positive cases (n¼1015) the most prevalent HR
genotypes detected were 16 (31.4%), 31 (22.6%), 18 (21.7%) and 58
(19.8%). The proportion of HR HPV cases attributable to types
included in currently licensed prophylactic HPV vaccines (HPV 16
and HPV 18) was 46% overall (n¼471 out of 1015) and 70% (n¼28
out of 40) for cases with severe cytological abnormalities. Here, 42%
(n¼430 out of 1015; 95% CI 39.4–45.5%) of HR HPV-positive cases
had an infection with a single HR type and in these women HPV 16
was the predominant genotype (n¼143 out of 430). The remaining
58% (n¼585 out of 1015; 95% CI 54.5–60.6%) had multiple HR
types and HPV 18 was the most predominant type detected (n¼201
out of 585). The prevalence of each HPV genotype in cases with a
single HR infection was compared with cases containing multiple HR
types and no statistically significant differences were found for HPV
16, 51 or 66 (w
2 test; P¼0.2594, P¼0.3461 and P¼0.6142
respectively). All other genotypes were statistically significantly
more common in cases with multiple HR types compared
with those with a single HR type (Figure 1). In cases with a single
HR type the genotype distribution in each cytology grade (negative,
borderline and dyskaryotic) was assessed. HPV 16 was the only
genotype significantly more prevalent in cases with dyskaryosis
(mild, moderate or severe) compared with borderline and negative
cases (Figure 2; w
2 test; P¼0.0395 and P40.0001 respectively).
Here, 66% of all HR and 57.6% of LR HPV cases were found in
women aged 30 years or less and the prevalence of HR cases
decreased progressively with age from 29.4% at 20–24 years to
1.4–2% at ages 50–65 years (Figure 3). In concordance, the
majority of all single HR cases (n¼262 out of 430) and cases with
multiple HR types (n¼411 out of 585) were found in women aged
30 years or less. Cases with multiple HR types were more common
than single HR cases in all women upto 44 years and this was
statistically significant in women aged 30 or less (20–24years
Po0.0001; 25–29years P¼0.0349).
HPV prevalence by cytology grade was calculated as a
percentage of the total number of women in the study population
classified as negative (n¼8434), borderline (n¼426), mild
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statistically significant increase in the proportion of HR HPV-
positive cases from 7% (n¼590 out of 8434) in cytology negative
samples up to 80% (n¼40 out of 50) with severe dyskaryosis
(Po0.0001). There was a limited variation between total HR HPV
prevalence in cases with borderline, mild, moderate and severe
dyskaryosis because of the many cases with multiple HR types in
all grades with abnormal cytology. In contrast, cases with a single
HR type predominated in women with severe dyskaryosis and this
was significant relative to their prevalence in negative, borderline,
mild and moderate cytology samples (Po0.0001; P¼0.0013;
P¼0.0100; P¼0.0135 respectively). Severe cytological abnormal-
ities were detected in 50 cases and 40 out of 50 were also HR HPV
positive: 21 out of 40 cases contained a single HR HPV infection 14
of which were positive for HPV 16 and in the remaining 19 out of
40 cases with multiple HR types 11 were HPV 16 positive. Here, 25
of the 366 LR HPV cases detected in this study population had an
abnormal cytology (classified as mild, moderate or severe).
Most of the women in the study were from the 50% least
deprived LSOA (64.8%) and the lowest HR HPV prevalence was
detected in the 50% least deprived LSOA in Wales (10.5%) with the
highest in the 10% most deprived LSOA (13.3%) according to SDS.
However, HR HPV cases were not significantly more prevalent in
any one rank (Figure 4).
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Figure 2 HR HPV type-specific prevalence by cytology grade in cases
with a single HR type (n¼430). HPV prevalence calculated as a percentage
of the total number of women in the study population classified as negative
(n¼8434), borderline (n¼426) and dyskaryotic (n¼219) cytology.
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Figure 3 HPV prevalence distribution by age. The total number of HR
HPV, single HR, multiple HR, and LR HPV cases in each age group was
calculated as a percentage of the total number of women in the study
population (9079) classified as 20–24years (n¼1578), 25–29years
(n¼1096), 30–34years (n¼1164), 35–39years (n¼1175), 40–44years
(n¼1157), 45–49years (n¼966), 50–54years (n¼739), 55–59years
(n¼694) and 60–64years (n¼510).
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Figure 4 HPV Prevalence Distribution with Social Deprivation Score.
The total number of HR HPV, single HR and multiple HR cases in each
LSOA rank was calculated as a percentage of the total number of women
in the study population (9079) classified as 10% most deprived LSOA
(n¼866), 10–20% most deprived LSOA (n¼512), 20–30% most
deprived LSOA (n¼673), 30–50% most deprived LSOA (n¼1144)
and 50% least deprived LSOA in Wales (n¼5884).
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Figure 1 Cross-sectional overview of HR HPV type distribution in South
Wales. The total number of HR HPV cases with single HR and multiple HR
types in each genotype calculated as a percentage of the total number of
positive cases (n¼1015). The HR HPV prevalence of each type in order of
predominance was as follows: HPV 16 (n¼319 31.4%), HPV 31 (n¼230
22.6%), HPV 18 (n¼221 21.7%), HPV 58 (n¼201 19.8%), HPV 33
(n¼151 14.9%), HPV 45 (n¼138 13.6%), HPV 39 (n¼126 12.4%), HPV
56 (n¼110 10.8%), HPV 59 (n¼109 10.7%), HPV 35 (n¼108 10.6%),
HPV 51 (n¼100 9.8%), HPV 66 (n¼89 8.8%), HPV 52 (n¼80 7.9%) and
HPV 68 (n¼25 2.5%). Single HR HPV type distribution (in order of
predominance): HPV 16 (n¼143 14.1%), HPV 66 (n¼40 3.9%), HPV 51
(n¼38 3.7%), HPV 31 (n¼31 3.1%), HPV 45 (n¼30 3.0%), HPV 39
(n¼30 3.0%), HPV 58 (n¼28 2.8%), HPV 59 (n¼26 2.6%), HPV 52
(n¼24 2.4%), HPV 18 (n¼20 2.0%), HPV 56 (n¼10 1.0%), HPV 68 (n¼5
0.5%), HPV 35 (n¼30 . 3 % ) ,a n dH P V3 3( n¼20 . 2 % ) .M u l t i p l eH RH P V
type distribution: HPV 18 (n¼201 19.8%), HPV 31 (n¼199 19.6%), HPV
16 (n¼176 17.3%), HPV 58 (n¼173 17.0%), HPV 33 (n¼149 14.7%),
HPV 45 (n¼108 10.6%), HPV 35 (n¼105 10.3%), HPV 56 (n¼100 5.5%),
HPV 39 (n¼96 9.5%), HPV 59 (n¼83 8.2%), HPV 51 (n¼62 6.1%), HPV
52 (n¼56 5.5%), HPV 66 (n¼49 4.8%), and HPV 68 (n¼20 2.0%).
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This is the largest type-specific investigation of HPV infection in
an unselected UK population to date, with an overall HPV
prevalence of 13.5% (9.3% age standardised). This baseline HPV
data was particularly robust for two reasons: (i) Samples were
anonymous and therefore did not require consent allowing
collection of consecutive samples from all women attending
routine cervical screening; (ii) A two-tier typing procedure was
followed in which HR-positive samples were identified and then
validated with a second HPV PCR before typing for 14 individual
HR HPV types, thus reducing the risk of false positive results.
Stringent quality control procedures were also employed involving
random retyping of 10% samples.
Within Europe, the closest comparative study was in Scotland
(Cuschieri et al, 2004), the overall HPV prevalence being 20.5%
(non age standardised), higher than in South Wales. However,
differences may be partially attributable to the methodologies
employed; in the Scottish study a subset of 3444 randomly selected
specimens with informed consent were analysed and successful
amplification with consensus primers was taken as a positive
result, whereas in the present study 10000 unselected samples were
processed and only those giving two consecutive positive results
were considered positive.
HR HPV conveys an increased risk of development of cervical
neoplasia and in this study HR HPV prevalence increased with
cytological abnormality (Bosch et al, 1995). A significantly higher
number of cases with a single HR type had severe dyskaryosis
compared with other cytology grades and no such correlation with
disease progression was found in cases with multiple HR types.
Others have recognised the clonal expansion of a single integrated
HR type and subsequent cervical neoplasia development (Vino-
kurova et al, 2005) and our data would support this observation
and suggests that there is little, if no, synergy between multiple
HPV types in terms of neoplastic effect (Fife et al, 2001). However,
the overall HPV type-specific distribution in cases with multiple
HR types is not a direct reflection of that observed in cases with a
single HR type, and of interest was the equivalent representation of
HPV 16 (Figure 1). HPV 16 is more persistent and aggressive than
other HR types (Smith et al, 2007) and our data suggests it is also
capable of creating an environment which is permissive to
secondary and/or co-infection with other HR types.
The highest HR HPV prevalence was found in women aged 30
years or less consistent with other findings (de Sanjose ´ et al, 2007)
and this is associated with a higher number of recent sexual
partners linked with this age group. In this study population, a
high number of cases with multiple HR types (58%) were observed
compared with other reports (Cuschieri et al, 2004). However, 70%
(n¼411 out of 585) of these women were aged 30 years or less and
more recent studies have observed an increasing number of
multiple infections within this age group (Sargent et al, 2008).
Further HPV type-specific PCR sequence analysis of cases with
multiple infections will be performed to confirm the QC validated
results obtained utilising the GP5/GP6þ HPV PCR-EIA assay.
The use of an anonymous screening population avoids many
potential sources of bias. However, it inevitably only includes
people who attend for their smears and we do not have data on the
HPV status of non-attendees. The reported correlation of increased
cervical cancer incidence associated with social deprivation (de
Sanjose ´ et al, 1997) is not reflected in our data and we observed no
significant increase in HPV prevalence in women from the most
deprived areas of South Wales. This may be because women from
areas of social deprivation are less likely to undergo cervical
screening.
We identified HPV 16, 31, 18 and 58 as the predominant HR types,
which is broadly consistent with other studies (Clifford et al,
2005a,b). Our data indicates that the prophylactic vaccination has
the potential to target HR types 16 and 18 in up to 46% of women
with negative cytology and 70% of cases with severe dyskaryosis in
South Wales. However, additional factors need to be considered
including vaccination uptake, successfully induced immunity and
residual susceptibility to carcinogenic HPV types. The vaccination
programme is likely to change HR HPV type-specific prevalence and
there is a need to include HPV genotyping assays into cervical
screening programmes to form a HPV type-specific surveillance to
monitor the efficacy of prophylactic vaccination. Our data represents
a baseline for future analyses in this population to monitor
vaccination programme effects on the prevalence of the vaccine-
targeted HR types 16 and 18, the proportion of cross-protection
provided to non-vaccine HR HPV types and the issue of type-
replacement. For the foreseeable future cytology will remain a key
part of cervical screening, however, changes to current screening
strategies are inevitable and there is only a short time frame for
incorporating robust HPV typing methods into routine settings.
In summary, current prevalence of HPV infection in South
Wales is 13.5% and half of all current HR HPV cases would be
targeted by the prophylactic HPV vaccines.
ACKNOWLEDGEMENTS
This study was funded by The Wales Office of Research and
Development for Health and Social Care (ReF05/1/014). We
gratefully acknowledge the work of the research staff and nurses
of the HPV Research Team, Department of Obstetrics &
Gynaecology, School of Medicine, Cardiff University who were
involved in primary sample handling and initial stages of sample
processing. The study was approved by South Wales Local
Research Ethics Committee. The authors’contributions are: S
Hibbitts (Corresponding author); project management, study
design, sample processing, data analysis, data interpretation and
writing of the paper; J Jones: sample processing and critical review
of the paper; N Powell: obtaining funding, assay design, data
interpretation and writing of the final report; N Dallimore: sample
processing and critical review of the paper; J McRea: cytology
sample processing and ensuring samples were anonymised; H
Beer: data processing and critical review of the paper; A Tristram:
conception, design and critical review of the study; H Fielder:
study design, ethical approval, project supervision and editing of
final paper; AN Fiander: conception, obtaining ethical approval,
study organisation and critical review of the paper.
REFERENCES
Bo ¨hmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU (2003) No
confirmed case of human papillomavirus DNA-negative cervical
intraepithelial neoplasia grade 3 or invasive primary cancer of the
uterine cervix among 511 patients. Am J Obstet Gynecol 189: 118–120
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman
MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human
papillomavirus in cervical cancer: a worldwide perspective. International
biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer
Inst 87: 796–802
Breslow NE, Day NE (1987) The design and analysis of cohort studies.
Statistical Methods in Cancer Research: Volume II 82: 1–406
Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh
PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de
Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ,
HPV prevalence in routine cervical smears, South Wales
S Hibbitts et al
1932
British Journal of Cancer (2008) 99(11), 1929–1933 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yFranceschi S, IARC HPV Prevalence Surveys Study Group (2005a)
Worldwide distribution of human papillomavirus types in cytologically
normal women in the International Agency for Research on Cancer HPV
prevalence surveys: a pooled analysis. Lancet 366: 991–998
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM
(2005b) Human papillomavirus genotype distribution in low-grade
cervical lesions: comparison by geographic region and with cervical
cancer. Cancer Epidemiol Biomarkers Prev 14: 1157–1164
Cotton SC, Sharp L, Little J, Duncan I, Alexander L, Cruickshank ME, Gray
NM, Jenkins D, Philips Z, Robertson A, Seth R, The TOMBOLA group
(2006) Trial of management of borderline and other low-grade abnormal
smears (TOMBOLA): Trial design. Contemp Clin Trials 5: 449–471
Coupe ´ VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ (2008) Age-
dependent prevalence of 14 high-risk HPV types in the Netherlands:
implications for prophylactic vaccination and screening. Br J Cancer
98(3): 646–651
Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C,
Gilkisson G, McGoogan E (2004) Multiple high risk HPV infections are
common in cervical neoplasia and young women in a cervical screening
population. J Clin Pathol 57: 68–72
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D,
McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C,
Ho L, Jacobs I, Pickles C, Sasieni P (2003) Management of women who
test positive for high-risk types of human papillomavirus: the HART
study. Lancet 362(9399): 1871–1876
de Sanjose ´ S, Bosch FX, Munoz N, Shah K (1997) Social differences in
sexual behaviour and cervical cancer. IARC Sci Publ 138: 309–317
de Sanjose ´ S, Diaz M, Castellsague ´ X, Clifford G, Bruni L, Mun ˜oz N, Bosch
FX (2007) Worldwide prevalence and genotype distribution of cervical
human papillomavirus DNA in women with normal cytology: a meta-
analysis. Lancet Infect Dis 7: 453–459
Department of Health News (2008) Department of Health awards
contract for HPV vaccine, http://nds.coi.gov.uk/Content/Detail.asp?
ReleaseID¼371095&NewsAreaID¼2
Fife KH, Cramer HM, Schroeder JM, Brown DR (2001) Detection of
multiple human papillomavirus types in the lower genital tract correlates
with cervical dysplasia. J Med Virol 64: 550–559
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A,
Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM,
Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline
HPV Vaccine Study Group (2004) Efficacy of a bivalent L1 virus-like
particle vaccine in prevention of infection with human papillomavirus
types 16 and 18 in young women: a randomised controlled trial. Lancet
364: 1757–1765
Hibbitts S, Rieck GC, Hart K, Powell NG, Beukenholdt R, Dallimore N,
McRea J, Hauke A, Tristram A, Fiander AN (2006) Human papilloma-
virus infection: an anonymous prevalence study in South Wales, UK. Br J
Cancer 95: 226–232
Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ,
Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-
enzyme immunoassay method for rapid detection of 14 high-risk and 6
low-risk human papillomavirus genotypes in cervical scrapings. J Clin
Microbiol 35: 791–795
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky
LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW,
Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego
JW, Sattler C, Barr E, Paavonen J (2007) Efficacy of a quadrivalent
prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-
like-particle vaccine against high-grade vulval and vaginal lesions: a
combined analysis of three randomised clinical trials. Lancet 369(9574):
1693–1702
Koutsky L (1997) Epidemiology of genital human papillomavirus infection.
Am J Med 102: 3–8
Krieger N, Quesenberry Jr C, Peng T, Horn-Ross P, Stewart S, Brown S,
Swallen K, Guillermo T, Suh D, Alvarez-Martinez L, Ward F (1999) Social
class, race/ethnicity, and incidence of breast, cervix, colon, lung, and
prostate cancer among Asian, Black, Hispanic, and White residents of the
San Francisco Bay Area, 1988–92 (United States). Cancer Causes Control
10: 525–537
Mun ˜oz N (2000) Human papillomavirus and cancer: the epidemiological
evidence. J Clin Virol 19: 1–5
National Assembly for Wales (2005) Welsh Index of Multiple Deprivation
2005. National Statistics Local Government Data Unit: Wales
NHS Cancer Screening Programmes (2004) Advice for cytopathology
laboratories on the implementation of liquid based cytology for cervical
screening. LBC Implementation Guide No 2 Version 1. Sheffield, UK
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmero ´n J, Wheeler CM, Chow
SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR,
Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W,
Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV
PATRICIA Study Group (2007) Efficacy of a prophylactic adjuvanted
bivalent L1 virus-like-particle vaccine against infection with human
papillomavirus types 16 and 18 in young women: an interim analysis of a
phase III double-blind, randomised controlled trial. Lancet 369(9580):
2161–2170
Parikh S, Brennan P, Boffetta P (2003) Meta-analysis of social inequality
and the risk of cervical cancer. Int J Cancer 105: 687–691
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M,
Elanko N, Coleman D, Yule R, Desai M (2004) Cervical HPV infection
and neoplasia in a large population-based prospective study: the
Manchester cohort. Br J Cancer 91: 942–953
Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M,
Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group
(2008) Prevalence of type-specific HPV infection by age and grade of
cervical cytology: data from the ARTISTIC trial. Br J Cancer 98(10):
1704–1709. e-pub ahead of print
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM
(2007) Human papillomavirus type distribution in invasive cervical
cancer and high-grade cervical lesions: a meta-analysis update. Int J
Cancer 121: 621–632
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler
CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE,
Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A,
Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen
KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic
quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-
like particle vaccine in young women: a randomised double-blind
placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:
271–278
Vinokurova S, Wentzensen N, Einenkel J, Klaes R, Ziegert C, Melsheimer P,
Sartor H, Horn LC, Ho ¨ckel M, von Knebel Doeberitz M (2005) Clonal
history of papillomavirus-induced dysplasia in the female lower genital
tract. J Natl Cancer Inst 97(24): 1816–1821
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Mun ˜oz N (1999) Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. JP a t h o l189: 12–19
Waterhouse J (2003) The European Standard Population (annex 5). World
Health Annual of Statistics. Cancer Incidence in Five Continents. IARC
WHO1976: Lyon 3: 456
Welsh Assembly Government News (2007) Vaccination against Cervical
Cancer to be introduced in Wales, http://www.wales.nhs.uk/newsitem.
cfm?contentid¼7808
HPV prevalence in routine cervical smears, South Wales
S Hibbitts et al
1933
British Journal of Cancer (2008) 99(11), 1929–1933 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y